POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
Potassium chloride provides potassium ions for maintenance of electrolyte balance and repolarization of cell membranes. Dextrose 5% provides caloric supplementation and may enhance potassium uptake into cells via insulin-mediated mechanisms. Lactated Ringer's solution provides isotonic crystalloid fluid, electrolytes (sodium, calcium, lactate), and buffer (bicarbonate precursor) to maintain intravascular volume and acid-base balance.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys (90%) and to a small extent via the gastrointestinal tract. Dextrose is metabolized via glycolysis to pyruvate, then enters the citric acid cycle or is stored as glycogen. Lactate is metabolized in the liver to glucose via gluconeogenesis or oxidized in various tissues. |
| Excretion | Potassium is primarily excreted renally (90%) via glomerular filtration and active secretion in the distal tubule; approximately 10% is lost in feces. In patients with normal renal function, urinary excretion is increased when intake is high. In the presence of renal impairment, elimination is decreased, leading to hyperkalemia risk. Dialysis (hemodialysis or peritoneal dialysis) can remove potassium. |
| Half-life | Potassium does not have a classical elimination half-life as it is an electrolyte with complex distribution and regulation. After a single IV dose, plasma levels decline rapidly due to redistribution, with an initial distribution half-life of about 1 hour. The terminal phase reflects slow equilibration with total body stores and is influenced by renal function; in anephric patients, the effective half-life is extended significantly. |
| Protein binding | Potassium is not significantly bound to plasma proteins; it is a free ion. Protein binding is negligible (<1%). |
| Volume of Distribution | Approximately 0.5-0.7 L/kg, reflecting distribution primarily in the extracellular fluid (ECF) and intracellular uptake. In hypokalemic states, the Vd may be larger due to intracellular depletion. Total body potassium is about 50 mEq/kg, with 98% intracellular. |
| Bioavailability | Oral potassium chloride: bioavailability is high (approximately 100%) for absorbed formulations, but first-pass extraction is minimal. However, absorption depends on formulation; liquid and effervescent tablets are nearly completely absorbed, whereas enteric-coated or extended-release forms may have slightly lower bioavailability due to incomplete release or binding. Intravenous administration yields 100% bioavailability. |
| Onset of Action | Intravenous administration: correction of hypokalemia begins within minutes, with maximal effect achieved in 1-2 hours depending on the infusion rate and concentration. Oral administration: onset is delayed, typically 1-2 hours for liquid formulations and 2-4 hours for extended-release tablets. |
| Duration of Action | Intravenous: duration depends on the underlying deficit; the effect is sustained for several hours after infusion, but continued supplementation may be needed to replete total body stores. Oral: duration of action is related to the rate of absorption and renal elimination; typically, effects last 4-6 hours for immediate-release and up to 12-24 hours for extended-release formulations. |
| Molecular Weight | 74.55 |
Intravenous infusion: 10–20 mEq/hour, not to exceed 20–40 mEq in 4 hours or 150 mEq per 24 hours. Rate: max 10 mEq/hour (1 mEq/mL concentration).
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 10–50 mL/min: reduce dose by 25–50%, monitor serum potassium. GFR < 10 mL/min: avoid or use extreme caution with close monitoring. |
| Liver impairment | No specific adjustment for Child-Pugh class A or B. Child-Pugh C: monitor potassium closely due to risk of hyperkalemia. |
| Pediatric use | 0.5–1 mEq/kg/dose IV, not to exceed 3 mEq/kg/day or 40 mEq/m²/day. Infusion rate: max 0.5–1 mEq/kg/hour. Use with dextrose 5% and lactated Ringer's as diluent. |
| Geriatric use | Start at lower end of dosing range (10 mEq over 4–6 hours), monitor renal function and serum potassium frequently due to age-related decline in GFR and increased risk of hyperkalemia. |
| 1st trimester | Potassium chloride is generally considered safe in the first trimester when used at recommended doses for electrolyte replacement. However, caution is advised as maternal electrolyte imbalances can affect fetal development. |
| 2nd trimester | Safe for use in the second trimester for treatment of hypokalemia, with monitoring to avoid hyperkalemia. |
| 3rd trimester | Safe for use in the third trimester; however, close monitoring of maternal potassium levels is recommended to prevent hyperkalemia which could affect uterine tone and fetal heart rate. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta via active transport and diffusion; fetal serum potassium levels are typically higher than maternal. Transfer is regulated to maintain fetal homeostasis, and exogenous potassium is unlikely to cause significant fetal toxicity at therapeutic doses. |
| Breastfeeding | Potassium chloride is considered compatible with breastfeeding. Potassium is a normal component of breast milk, and supplementation at recommended doses does not pose a risk to the infant. However, high maternal doses may lead to elevated milk potassium levels, though clinical significance is unlikely. |
| Lactation Rating | L1: Compatible |
| Teratogenic Risk | Potassium chloride is a normal body constituent; no teratogenic risk at therapeutic doses. Dextrose and lactated Ringer's are standard IV fluids. No evidence of fetal harm. |
| Fetal Monitoring | Monitor serum potassium, ECG, renal function, and fluid status. Fetal heart rate monitoring if maternal electrolyte imbalance occurs. |
| Fertility Effects | No known effects on fertility. Reproductive toxicity studies not conducted; unlikely to impair fertility at therapeutic doses. |
■ FDA Black Box Warning
Potassium chloride must be diluted and administered slowly to avoid fatal hyperkalemia and cardiac arrhythmias. Rapid intravenous infusion of concentrated potassium solutions can cause cardiac arrest.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAcute dehydrationConcurrent use of potassium-sparing diuretics (e.g., spironolactone, eplerenone) without close monitoringAddison's diseaseCrush syndrome or extensive tissue breakdown
| Precautions | Monitor serum potassium levels frequently during administration, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Severe hyperkalemia can cause muscle weakness, paralysis, life-threatening cardiac arrhythmias, and cardiac arrest, Extravasation may cause tissue necrosis, Not for direct intravenous infusion without proper dilution |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (bananas, oranges, tomatoes, spinach, potatoes, avocados) and potassium-containing salt substitutes during treatment to prevent hyperkalemia. Dietary adjustments should be guided by serum potassium levels. |
| Clinical Pearls | This combination product is used for correction of hypokalemia and fluid/electrolyte maintenance. Assess renal function before administration; risk of hyperkalemia in renal impairment. Do not administer undiluted; ensure IV line compatibility (potassium and calcium in LR may precipitate in certain conditions). Monitor serum potassium and cardiac function during infusion; rate should not exceed 10 mEq/hour via peripheral line. Invert bag to ensure mixing before use. |
| Patient Advice | This medication is given through a vein to treat low potassium and provide fluids. · Tell your doctor if you have kidney problems, heart disease, or are on any medications. · Report any symptoms of high potassium like muscle weakness, irregular heartbeat, or tingling. · Do not suddenly stop drinking potassium-rich foods unless advised. · You may experience pain or redness at the IV site; inform nurse. |
Loading safety data…